Mayo Clinic Ovarian Cancer Trials

10031 A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
   About this study: This trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors.
   Target Population: Solid tumor malignancy that is unresectable or metastatic and for which standard treatment is not available
   Treatment Line: 3rd line or greater
   Principal Investigator: Andrea E. Wahner Hendrickson, M.D.

Opening soon-

NRG GY019 A Randomized Phase III, Two Arm Trial of Paclitaxel/ Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV in Primary Low Grade Serous Carcinoma of the Ovary or Peritoneum
   About this study: Hormonal Therapy: Maintenance or Adjuvant
   Target Population: Newly diagnosed stage II-IV or invasive micropapillary serous cancer, no prior chemo or hormonal therapy
   Treatment Line: 1st line
   Principal Investigator: Gretchen E. Glaser, M.D.

GOG3026 A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
   About this study: To determine the progression-free survival of women receiving the combination of letrozole + Ribociclib.
   Target Population: Recurrent, low-grade, measurable, serous carcinoma
   Treatment Line: 2nd or greater
   Principal Investigator: S. John Weroha, M.D., Ph.D.

Misp54450 Pembrolizumab Monotherapy in Recurrent Ovarian Cancer: NanoString Gene Expression Profiling
   About this study: The tumor is tested using NanoString gene profiling. This determines if the cancer is immunoreactive. Immunoreactive subtypes are then treated with pembrolizumab immunotherapy.
   Target Population: Recurrent ovarian cancer
   Treatment Line: 2nd line or greater
   Principal Investigator: Andrea E. Wahner Hendrickson, M.D.

Interested in Clinical Trials?

For more information, please call Mayo Clinic Office of Clinical Trials at 855-776-0015 (toll free) or www.mayo.edu/research/clinical-trials
UC-IRB13-1235 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer

About this study: To determine if the addition of metformin to standard adjuvant or neoadjuvant chemotherapy plus extended metformin beyond standard chemotherapy increases progression free survival.

Target Population: Primary ovarian cancer, stage III or IV; planned for neoadjuvant chemotherapy; or primary cytoreductive surgery optimally debulked OR suboptimally debulked with microscopic disease

Principal Investigator: Sean C. Dowdy, M.D.

MC1511 Phase 1 Pilot Study of Curcumin and Piperine to Derive a Safe, Optimal Biologic Dose for Ureteral Stent-Induced Symptoms

About this study: Ureteral stents can cause severe symptoms yet are necessary; our goal is to reduce inflammation for ureteral stent-induced symptoms in patients with cancer.

Target Population: Primary ovarian, fallopian tube or primary peritoneal cancer with a ureteral stent in place

Treatment Line: Symptom control

Principal Investigator: Aminah Jatoi, M.D.

MC1266 Phase I/II Trial of Intraperitoneal Administration of adipose tissue derived mesenchymal stem cells infected with a NIS-Expressing Derivative Manufactured from a Genetically Engineered Strain of Measles Virus in Patients with Recurrent Ovarian Cancer

About this study: This trial studies the side effects and best dose of oncolytic measles virus infected mesenchymal stem cells and to see how well it works in treating patients with recurrent ovarian cancer. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian cancer cells.

Target Population: Recurrent or progressive disease

Treatment Line: 2nd line or greater

Principal Investigator: Matthew S Block MD PhD

MC1365 A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator’s Choice Chemotherapy for Patients with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

About the study: This randomized trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compares to investigator’s choice chemotherapy in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

Target Population: Recurrent, persistent, or progressive platinum-resistant disease randomized to receive measles virus or traditional chemotherapy.

Treatment Line: 2nd line or greater

Principal Investigator: Matthew S Block MD PhD